NxStage Stock Receives a Third Buy Rating in a Row
BTIG, Piper Jaffray, and Northland Securities have all assigned Buy ratings to NxStage, which trades as NXTM on the NASDAQ. In the past quarter, more insiders have been buying the stock.
Read the full article » | Posted 04-12-2017
Related Articles
- Update on H.R. 8875 “Improving Home Dialysis Act of 2026.” Posted 07-16-2026
- Stickman Industries Offers Many Products for Home Dialysis Patients Posted 07-16-2026
- Who Qualifies for Home Dialysis? Posted 07-16-2026
- NxStage’s ICan Tool Can Help HD Patients Learn to Self-cannulate Posted 07-16-2026

